E-LIB Suche - Ergebnisse für: Sharon, Elad

1

Sars-Cov-2 Vaccination in the First Year after Hematopoieti..:

Hill, Joshua A. ; Martens, Michael J. ; Young, Jo-Anne H....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S82-S83 , 2024

Link: https://doi.org/10.1016/..

2

Clinical outcomes and safety of immune checkpoint inhibitor..:

Nassar, Amin H ; El Zarif, Talal ; Khalid, Ahmed Bilal...
Journal for ImmunoTherapy of Cancer. 12 (2024) 3 - p. e008724 , 2024

Link: https://doi.org/10.1136/..

3

Using multi-scale genomics to associate poorly annotated ge..:

Canavati, Christina ; Sherill-Rofe, Dana ; Kamal, Lara...
Genome Medicine. 16 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

4

Ziv-aflibercept plus pembrolizumab in patients with advance..:

Baginska, Joanna ; Nau, Allison ; Gomez Diaz, Ilana...
Cancer Immunology, Immunotherapy. 73 (2024) 1 - p. , 2024

Link: https://doi.org/10.1007/..

5

SARS-CoV-2 vaccination in the first year after hematopoieti..:

Hill, Joshua A ; Martens, Michael J ; Young, Jo-Anne H...
Clinical Infectious Diseases. , 2024

Link: https://doi.org/10.1093/..

6

Correlation between tumor size change and outcome in a rare..:

Othus, Megan ; Patel, Sandip P ; Chae, Young K...
JNCI: Journal of the National Cancer Institute. 116 (2024) 5 - p. 673-680 , 2024

Link: https://doi.org/10.1093/..

7

SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced..:

Patel, Sandip P. ; Guadarrama, Elizabeth ; Chae, Young Kwang...
Cancer. , 2024

Link: https://doi.org/10.1002/..

8

Exacerbation of CMV and Nontuberculous Mycobacterial Infect..:

Anidi, Ifeanyichukwu U ; Sakai, Shunsuke ; Brooks, Kelsie...
Open Forum Infectious Diseases. 11 (2024) 5 - p. , 2024

Link: https://doi.org/10.1093/..

9

Ipilimumab with or without nivolumab in PD-1 or PD-L1 block..:

VanderWalde, Ari ; Bellasea, Shay L. ; Kendra, Kari L....
Nature Medicine. 29 (2023) 9 - p. 2278-2285 , 2023

Link: https://doi.org/10.1038/..

10

Society for Immunotherapy of Cancer (SITC) checkpoint inhib..:

Tawbi, Hussein A ; Sullivan, Ryan J ; Feltquate, David...
Journal for ImmunoTherapy of Cancer. 11 (2023) 7 - p. e007309 , 2023

Link: https://doi.org/10.1136/..

11

Design of phase II oncology trials evaluating combinations ..:

Sharon, Elad ; Foster, Jared C
JNCI: Journal of the National Cancer Institute. 115 (2023) 6 - p. 613-618 , 2023

Link: https://doi.org/10.1093/..

12

The Cancer Moonshot Immuno-Oncology Translational Network a..:

Annapragada, Ananth ; Sikora, Andrew G ; Marathe, Himangi...
JNCI: Journal of the National Cancer Institute. 115 (2023) 11 - p. 1262-1270 , 2023

Link: https://doi.org/10.1093/..

13

Society for Immunotherapy of Cancer (SITC) consensus defini..:

Kluger, Harriet ; Barrett, J Carl ; Gainor, Justin F...
Journal for ImmunoTherapy of Cancer. 11 (2023) 3 - p. e005921 , 2023

Link: https://doi.org/10.1136/..

14

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: c..:

Zhang, Tian ; Forde, Patrick M ; Sullivan, Ryan J...
Journal for ImmunoTherapy of Cancer. 11 (2023) 5 - p. e006555 , 2023

Link: https://doi.org/10.1136/..

15

Dasatinib/prednisone induction followed by blinatumomab/das..:

Advani, Anjali S. ; Moseley, Anna ; O'Dwyer, Kristen M....
Blood Advances. 7 (2023) 7 - p. 1279-1285 , 2023

Link: https://doi.org/10.1182/..